Tuberculous monoarthritis after treatment with adalimumab in Crohn's disease Monoartritis tuberculosa tras tratamiento con adalimumab en enfermedad de Crohn

Tuberculous monoarthritis after treatment with adalimumab in Crohn's disease Monoartritis tuberculosa tras tratamiento con adalimumab en enfermedad de Crohn

Bibliographic Details
Main Authors:	Alejandro Martínez-Caselles, Cristina Martínez-Pascual, María Muñoz-Tornero, Antonio Sánchez-Torres, Fernando Carballo-Álvarez
Format:	Article
Language:	English
Published:	Aran Ediciones 2012-03-01
Series:	Revista Espanola de Enfermedades Digestivas
Online Access:	http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082012000300015

Similar Items

Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease Eficacia del adalimumab en el tratamiento de las manifestaciones extraintestinales de la enfermedad de Crohn
by: Manuel Barreiro-de-Acosta, et al.
Published: (2012-09-01)

Tratamiento de inducción y mantenimiento con adalimumab en la enfermedad de Crohn: un estudio abierto Adalimumab induction and maintenance therapy from Crohn's diseas: An open-label study
by: N. López Palacios, et al.
Published: (2008-11-01)

Adalimumab for the treatment of Crohn&rsquo;s disease
by: Andrea Cassinotti, et al.
Published: (2008-09-01)

Review: Efficacy and safety of adalimumab in Crohn's disease
by: Gary R. Lichtenstein, et al.
Published: (2008-07-01)

Crohn’s Disease Associated Pyoderma Gangrenosum Treated with Adalimumab
by: Despoina Kakagia, et al.
Published: (2012-03-01)

Leukocytoclastic Vasculitis Associated with Adalimumab Therapy for Crohn’s Disease
by: Lankai Cathy Xu, et al.
Published: (2023-03-01)

Adalimumab and azathioprine in the prevention of postoperative crohn’s disease recurrence
by: A. V. Poletova, et al.
Published: (2020-10-01)

Efficacy of adalimumab for Crohn’s disease in real clinical practice
by: O V Knyazev, et al.
Published: (2017-02-01)

CROHN'S DISEASE: GENERAL CHARACTERISTICS AND TREATMENT WITH ADALIMUMABE BIOPHARMACEUTICAL
by: S. A. Marques, et al.
Published: (2018-02-01)

Listeria Monocytogenes Brain Abscess in Crohn’s Disease Treated with Adalimumab
by: Amporn Atsawarungruangkit, et al.
Published: (2017-11-01)

Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab
by: Zeisler B, et al.
Published: (2015-04-01)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
by: Jong Pil Im
Published: (2017-04-01)

Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease
by: Yifei Liu, et al.
Published: (2022-07-01)

Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease
by: Liang Chen, et al.
Published: (2022-08-01)

Isolated Bilateral Gastrocnemius Myositis in Crohn Disease Successfully Treated with Adalimumab
by: Salvatore Vadala di Prampero, et al.
Published: (2016-11-01)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
by: Song Christine H, et al.
Published: (2012-11-01)

HEPATITIS AND PNEUMONITIS DURIN ADALIMUMAB THERAPY IN CROHN? DISEASE: mind the histoplasmosis!
by: Bruno do Valle PINHEIRO, et al.
Published: (2014-03-01)

Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
by: Carlos Henrique Marques dos Santos
Published: (2014-07-01)

Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.
by: Reenaers, C, et al.
Published: (2013)

Langerhans Cell Histiocytosis Caused by Adalimumab for Crohn’s Disease: A Case Report
by: Mariko Kochi, et al.
Published: (2023-06-01)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
by: Arne Carlsen, et al.
Published: (2018-03-01)

Vitiligo during Treatment of Crohn’s Disease with Adalimumab: Adverse Effect or Co-Occurrence
by: Celia Posada, et al.
Published: (2011-02-01)

Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
by: Mauro Mastronardi, et al.
Published: (2019-11-01)

Antineutrophil cytoplasmic antibodies associated vasculitis in patient with Crohn's disease treated with adalimumab
by: Carmen Martín Varas, et al.
Published: (2017-09-01)

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
by: Tsutomu Mizoshita, et al.
Published: (2016-06-01)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
by: Taketo Suzuki, et al.
Published: (2019-02-01)

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
by: Reenaers, C, et al.
Published: (2012)

Adalimumab induction therapy achieves clinical remission and response in Chinese patients with Crohn's disease
by: Wu, K, et al.
Published: (2015)

Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
by: Juntao Yin, et al.
Published: (2022-09-01)

Fulminant Herpes Simplex Hepatitis Secondary to Adalimumab in Crohn’s Disease: A Case Report
by: Kanika Goel, et al.
Published: (2019-07-01)

Crohn's-like disease in a patient with common variable immunodeficiency treated with azathioprine and adalimumab
by: Juan María Vázquez-Morón, et al.
Published: (2013-06-01)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
by: Martin Wasserbauer, et al.
Published: (2022-01-01)

Adalimumab - an effective and promising treatment for patients with fistulizing Crohn's disease: a case series
by: Simopoulos Konstantinos, et al.
Published: (2011-03-01)

Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease
by: Arne Carlsen, et al.
Published: (2020-06-01)

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica
by: Patricia Cordero-Ruiz, et al.
Published: (2011-06-01)

Efectividad y seguridad en nuestro entorno de adalimumab como tratamiento anti-TNF de primera linea en niños con enfermedad de Crohn
by: Víctor Manuel Navas-López, et al.
Published: (2018-02-01)

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
by: Wu, K, et al.
Published: (2016)

Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn’s Disease?
by: Beraldo RF, et al.
Published: (2020-08-01)

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
by: Kai-Chun Wu, et al.
Published: (2016-04-01)